Absence of MMP2 expression correlates with poor clinical outcomes in rectal cancer, and is distinct from MMP1-related outcomes in colon cancer

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 4167-4176

  Wong, John C T ^a   Chan, Simon K ^b   Schaeffer, David F ^a   Sagaert, Xavier ^c   Lim, Howard J ^b   Kennecke, Hagen ^b   Owen, David A ^a   Suh, Kwang W ^d   Kim, Young Bae ^d   Tai, Isabella T ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CELL INVASION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MMP1 GENE; MMP2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; RECURRENCE; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 79959277702     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1224     Document Type: Article

References (39)

1. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990:322:352-8. (Pubitemid 20042739)
2. Marshall JL, Haller DG, de Gramont A, Hochster HS, Lenz HJ, Ajani JA, et al. Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res 2007;1:146-54.
3. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-19. (Pubitemid 41103700)
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-5. (Pubitemid 39429665)
5. Köckerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W, et al. (Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol 1998;16:324-9.
6. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. German Rectal Cancer Study Group. Preoperative versus post-operative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
7. Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006,24:4620-5. (Pubitemid 46630960)
8. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006,355:1114-23. (Pubitemid 44394918)
9. National Institutes of Health Consensus Conference: adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444.
10. Minsky BD, Röedel C, Valentini V. Combined modality therapy for rectal cancer. Cancer J 2010;16:253-61.
11. Puli SR, Bechtold ML, Reddy JB, Choudhary A, Antillon MR, Brugge WR, et al. How good is endoscopic ultrasound in differentiating various T stages of rectal cancer? Meta-analysis and systematic review. Ann Surg Oncol 2009;16:254-65.
12. Puli SR, Reddy JB, Bechtold ML, Choudhary A, Antillon MR, Brugge WR, et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009;16:1255-65.
13. Rafaelsen SR, Sørensen T, Jakobsen A, Bisgaard C, Lindebjerg J. Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. Scand J Gastroenterol 2008;43:440-6. (Pubitemid 351450982)
14. Yan DW, Li DW, Yang YX, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer 2010;103:961-9.
15. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010 Jul 10;28:3219-26.
16. Chan SK, Griffith OL, Tai IT, Jones SJ. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008;17:543-52. (Pubitemid 351469203)
17. Alibes A, Yankilevich P, Canada A, Díaz-Uriarte R. IDconverter and IDClight: conversion and annotation of gene and protein Ids. BMC Bioinformatics 2007;8:9.
18. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006;24;5043-51. (Pubitemid 46631408)
19. Boon K, Osorio EC, Greenhut SF, Schaefer CF, Shoemaker J, Polyak K, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci USA 2002;99:11287-92. (Pubitemid 34920918)
20. American Cancer Society: Cancer Facts and Figures. 5/10 update. Available from: http://www.cancer.org/Research/CancerFactsFigures/index
21. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-94.
22. Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F, et al. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 2009;29:67-74.
23. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
24. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004;23:119-35.
25. Sunami E, Tsuno N, Osada T, Saito S, Kitayama J, Tomozawa S, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist 2000;5:108-14. (Pubitemid 30238230)
26. Shiozawa J, Ito M, Nakayama T, Nakashima M, Kohno S, Sekine I, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol 2000;13:925-33.
27. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kössi J, Hirsimäki P, et al. Prognostic significance of matrix metalloproteinases -1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007;121:714-23. (Pubitemid 47106199)
28. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE, et al. (Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
29. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999;20:749-55. (Pubitemid 29191855)
30. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997;277:225-8. (Pubitemid 27446075)
31. Li BH, Zhao P, Liu SZ, Yu YM, Han M, Wen JK. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in colorectal carcinoma invasion and metastasis. World J Gastroenterol 2005;11:3046-50 (Pubitemid 40790660)
32. Waas ET, Hendriks T, Lomme RM, Wobbes T. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005;48:700-10. (Pubitemid 40880716)
33. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995;1:899-906.
34. Inafuku Y, Furuhata T, Tayama M, Okita K, Nishidate T, Mizuguchi T, et al. Matrix metalloproteinase-2 expression in stromal tissues is a consistent prognostic factor in stage II colon cancer. Cancer Sci 2009;100:852-8.
35. Habermann JK, Paulsen U, Roblick UJ, Upender MB, McShane LM, Korn EL, et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007;46:10-26. (Pubitemid 44772868)
36. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, et al. A phosphatase associated with metastasis of colorectal cancer. Science 2001;294:1343-6.
37. Yanagawa R, Furukawa Y, Tsunoda T, Kitahara O, Kameyama M, Murata K, et al. Genome-wide screening of genes showing altered expression in liver metastases of human colorectal cancers by cDNA microarray. Neoplasia 2001;3:395-401. (Pubitemid 32988809)
38. Ki DH, Jeung HC, Park CH, Kang SH, Lee GY, Lee WS, et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int J Cancer 2007;121:2005-12.
39. Lin HM, Chatterjee A, Lin YH, Anjomshoaa A, Fukuzawa R, McCall JL, et al. Genome wide expression profiling identifies genes associated with colorectal liver metastasis. Oncol Rep 2007;17:1541-9.